Overview
Overview
Oxytocin is a peptide hormone (nonapeptide) known for its role in childbirth and lactation, and it also influences social bonding and behavior[1]. In research settings, synthetic oxytocin is used to explore effects ranging from stress and anxiety to social cognition[2]. Oxytocin 5 mg is available as a lyophilized powder for research use[3], requiring reconstitution before dosing. This protocol compiles evidence‑based guidance on dosing, administration, and storage for oxytocin peptide. Reconsti
- Category
- Fertility
- Routes
- subcutaneous
Mechanism
Oxytocin
Mechanism of action
Mechanism of action
Oxytocin exerts its effects by binding to oxytocin receptors (OXTR), which are G‑protein coupled receptors widely expressed in both central and peripheral tissues [6] . In the brain, oxytocin acts as a neuromodulator: it is produced in the hypothalamus and released from the posterior pituitary, and also directly released within brain regions involved in emotion and social behavior. Activation of central OXTR influences neurotransmitter systems (e.g., enhancing prosocial signaling via dopamine and reducing stress responses via the hypothalamic–pituitary–adrenal axis) [7] . These actions underlie oxytocin’s observed effects on increasing trust, empathy, and social bonding. Peripherally, oxytocin causes contraction of smooth muscles—for example, uterine muscle contraction during labor and milk ejection in lactation [1] . It also can modulate pain perception and inflammation; studies show subcutaneous oxytocin produces local analgesia, likely by acting on sensory nerves or immune cells in skin tissue [8] . Importantly, oxytocin does not significantly cross the blood–brain barrier from the bloodstream. Thus, peripheral administration primarily targets peripheral OXTR (with some indirect central effects), while intranasal administration is thought to better engage central receptors by bypassing the blood–brain barrier. Overall, oxytocin’s mechanism in research contexts involves enhancing social‑affiliative behaviors and modulating physiological stress and metabolic processes through its receptor‑mediated signaling pathways.
Key research findings
- 01
Nonapeptide (9 amino acids) with an intramolecular disulfide bridge; it was the first peptide hormone to be sequenced and chemically synthesized (du Vigneaud, 1953; Nobel Prize in Chemistry 1955) (established biochemistry / historical).
- 02
Differs from the related posterior-pituitary peptide vasopressin by only two amino acids and acts on a related family of G-protein-coupled receptors, making receptor selectivity an important research consideration (established biochemistry).
- 03
Acts on the oxytocin receptor (OXTR, a GPCR); peripherally this is linked to uterine smooth-muscle contraction and milk ejection via mammary myoepithelial cells (established physiology).
- 04
Extensively studied in behavioral neuroscience for central roles in social bonding and affiliative behavior, notably in prairie-vole pair-bonding models (animal model).
- 05
Intranasal delivery is a widely used research route for probing central/behavioral effects in humans, though the extent and route of brain penetration remain actively debated in the literature (human study / methodological).
- 06
Has a short circulating half-life (on the order of minutes), reflecting rapid enzymatic degradation (established pharmacology).
Primary source: Approved IV obstetric use Autism spectrum disorder Social cognition in healthy adults Other research areas Anxiety and PTSD: Small RCTs and reviews suggest possible reductions in amygdala reactivity, but no large Phase 3 evidence supports clinical use. Pain and migraine: Small human trials of intranasal oxytocin for migraine and chronic pain have produced mixed signals; not a standard treatment. Obesity and metabolism: Early human trials of intranasal oxytocin and body weight have shown modest signals in some studies but inconsistent results overall. Sleep apnea: Mechanistic work shows oxytocin's role in cardiac vagal neurons and breathing; early clinical signals for obstructive sleep apnea exist but are preliminary.
Pharmacokinetic profile
Single-dose plasma curve over 24h. Shaded band = commonly-cited therapeutic window. Illustrative only.
Protocol Reference
Protocol reference
Commonly cited research range: 100–500 mcg, daily.
Reference figures reported in the research literature — not a dosing recommendation. For interactive vial math and scheduling, see the Calculator and Schedule tabs.
Cited protocol & reconstitution guide
Source-backed reference fields by phase, including any volume fields authored in the cited guide.
SubQ – Low
100 mcg
SubQ – Moderate
200-300 mcg
SubQ – Upper
400-500 mcg
| Phase | Reference amount | Units / volume |
|---|---|---|
| SubQ – Low | 100 mcg | 6 units (0.06 mL) |
| SubQ – Moderate | 200-300 mcg | 12–18 units (0.12–0.18 mL) |
| SubQ – Upper | 400-500 mcg | 24–30 units (0.24–0.30 mL) |
Titration protocol
- SubQ – LowStart100 mcg
Once daily subcutaneous. Rotate injection sites; hold at this level before any step up.
- SubQ – ModerateBuild200-300 mcg
Once daily subcutaneous. Rotate injection sites; standard research cycle structure runs 4–6 weeks with a review point at week 4.
- SubQ – UpperMaintenance400-500 mcg
Once daily subcutaneous. Upper end of the documented research range — do not exceed; follow the 4–6 week cycle with a 1–2 week off period.
Storage & Handling
Storage requirements(typical for most peptides)
Can be stored for extended periods. Protect from moisture.
Store in refrigerator door. Never freeze after reconstitution.
Label vials with reconstitution date. Discard if cloudy.
Reconstitution steps
- 01🌡️Inspect the vial: check label for compound name, vial size, lot number, expiry; confirm the lyophilized cake looks intact.
- 02🧴Draw 3 mL bacteriostatic water into a sterile syringe — this 5 mg vial yields 1.67 mg/mL.
- 03💉Wipe the stoppers: swab the BAC water vial stopper and the peptide vial stopper with separate sterile alcohol pads.
- 04💧Inject slowly down the vial wall: angle the needle so water runs down the inside wall rather than directly onto the powder.
- 05🔄Swirl gently: roll or swirl until the cake fully dissolves; do not shake hard (mechanical foaming can damage peptides).
- 06🏷️Inspect and refrigerate: solution should be clear and free of particulates; store at 2–8 °C (35.6–46.4 °F), protected from light. Do not freeze; discard if cloudy or particulates develop.
- 07❄️Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Additional storage notes
Store at −20 °C (−4 °F) or lower for long‑term storage; refrigerate at 2–8 °C (35.6–46.4 °F) for shorter periods. Protect from light and moisture.
Refrigerate at 2–8 °C (35.6–46.4 °F); stable for up to 28–30 days with bacteriostatic water. Mark date of reconstitution and discard after 4 weeks.
Can aliquot reconstituted solution into sterile vials and freeze at −20 °C (−4 °F). Do not subject to repeated freeze–thaw cycles ; thaw each aliquot only once.
Allow vials to reach room temperature before opening to reduce condensation uptake.
Clinical Evidence
Clinical evidence
Extensively researched in physiology and behavioral neuroscience; intranasal delivery is a common research route for central effects.
Approved IV obstetric use Autism spectrum disorder Social cognition in healthy adults Other research areas Anxiety and PTSD: Small RCTs and reviews suggest possible reductions in amygdala reactivity, but no large Phase 3 evidence supports clinical use. Pain and migraine: Small human trials of intranasal oxytocin for migraine and chronic pain have produced mixed signals; not a standard treatment. Obesity and metabolism: Early human trials of intranasal oxytocin and body weight have shown modest signals in some studies but inconsistent results overall. Sleep apnea: Mechanistic work shows oxytocin's role in cardiac vagal neurons and breathing; early clinical signals for obstructive sleep apnea exist but are preliminary.
- 01Nonapeptide (9 amino acids) with an intramolecular disulfide bridge; it was the first peptide hormone to be sequenced and chemically synthesized (du Vigneaud, 1953; Nobel Prize in Chemistry 1955) (established biochemistry / historical).
- 02Differs from the related posterior-pituitary peptide vasopressin by only two amino acids and acts on a related family of G-protein-coupled receptors, making receptor selectivity an important research consideration (established biochemistry).
- 03Acts on the oxytocin receptor (OXTR, a GPCR); peripherally this is linked to uterine smooth-muscle contraction and milk ejection via mammary myoepithelial cells (established physiology).
- 04Extensively studied in behavioral neuroscience for central roles in social bonding and affiliative behavior, notably in prairie-vole pair-bonding models (animal model).
- 05Intranasal delivery is a widely used research route for probing central/behavioral effects in humans, though the extent and route of brain penetration remain actively debated in the literature (human study / methodological).
- 06Has a short circulating half-life (on the order of minutes), reflecting rapid enzymatic degradation (established pharmacology).
Evidence maturity varies by compound; much peptide research is preclinical (in vitro or animal-model). Where human data are limited, findings should be read as research observations, not clinical conclusions.
References
Literature references
Published research articles and sources related to Oxytocin.
- 01U.S. Food and Drug Administration Oxytocin Injection, USP (synthetic) - Current FDA label (NDA 018261 / 018248). FDA Drugs@FDA (2022)et al. (2022)
- 02U.S. Food and Drug Administration Pitocin (oxytocin injection, USP) - Prescribing information (NDA 018261). FDA Drugs@FDA (2021)et al. (2021)
- 03Sikich L, Kolevzon A, King BH, McDougle CJ, et al. Intranasal Oxytocin in Children and Adolescents with Autism Spectrum Disorder. New England Journal of Medicine (2021)et al. (2021)
- 04Kosfeld M, Heinrichs M, Zak PJ, Fischbacher U, Fehr E. Oxytocin increases trust in humans. Nature (2005)et al. (2005)
- 05Quintana DS, Westlye LT, et al. Advances in the field of intranasal oxytocin research: lessons learned and future directions for clinical research. Molecular Psychiatry / PMC (2021)et al. (2021)
- 06Martins D, Brodmann K, Veronese M, et al. "Less is more": a dose-response account of intranasal oxytocin pharmacodynamics in the human brain. bioRxiv (preprint, Imperial College London team) (2021)et al. (2021)
- 07Higgins DT, Sutton MM, et al. Plasma pharmacokinetics of intravenous and intranasal oxytocin in nonpregnant adults. Peptides / PubMed (2025)et al. (2025)
- 08Audunsdottir K, Sartorius AM, Kang H, et al. The effects of oxytocin administration on social and routinized behaviors in autism: a preregistered systematic review and meta-analysis. Psychoneuroendocrinology (2024)et al. (2024)
- 09Ooi YP, Weng SJ, Kossowsky J, Gerger H, Sung M. Oxytocin and Autism Spectrum Disorders: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Pharmacopsychiatry (2017)et al. (2017)
- 10Keech B, Crowe S, Hocking DR. Intranasal oxytocin, social cognition and neurodevelopmental disorders: A meta-analysis. Psychoneuroendocrinology (2018)et al. (2018)
- 11National Center for Biotechnology Information Oxytocin (Compound CID 439302) - structure and properties. PubChem (2026)et al. (2026)
- 12Waltenspuhl Y, Schoppe J, Ehrenmann J, et al. Crystal structure of the human oxytocin receptor. Science Advances / bioRxiv preprint (2020)et al. (2020)
- 13ClinicalTrials.gov (NICHD) SOARS-B: Study of Oxytocin in Autism to improve Reciprocal Social Behaviors (NCT01944046). ClinicalTrials.gov (2021)et al. (2021)
Observed Effects
Observed effects in cited research
IV / IM obstetric label safety (FDA)
- Uterine hyperstimulation, uterine rupture, postpartum hemorrhage.
- Water intoxication with seizures and coma, linked to oxytocin's antidiuretic effect during long infusions.
- Maternal arrhythmias, premature ventricular contractions, hypertension or hypotension.
- Fetal bradycardia, arrhythmia, hypoxia, and neonatal complications.
Water intoxication is dose-related
- The water-intoxication risk in the FDA label is tied to long, high-rate IV infusion. Single low-IU intranasal research doses do not carry the same risk profile, but it is still a documented oxytocin effect and a reason high-dose intranasal regimens deserve clinician oversight.
Study and material context
Intranasal route (research context)
- Mild nasal irritation, sneezing, runny nose.
- Transient headache or fatigue.
- Occasional reports of irritability or mood changes, particularly at higher doses.
- SOARS-B (24-week, N=290) reported no oxytocin-vs-placebo difference in serious adverse events.
Subcutaneous route (research context)
- Injection-site redness, bruising, or soreness.
- Short peripheral plasma spikes; no clear central nervous system effects.
- Quality control risk: research-use peptide vials vary in purity and require batch COA review.
Research Considerations
Research considerations
Research Use Only - not for human or veterinary therapeutic use. Has been studied in clinical research; on this platform it is handled strictly as a research material. Consult a licensed healthcare professional for any clinical decisions.
- Pregnancy: oxytocin should never be used during pregnancy outside of approved medical induction in a hospital. Inappropriate use can cause uterine rupture, fetal distress, or worse.
- Cardiovascular conditions: the FDA label notes risks of arrhythmia and water intoxication; people with cardiovascular disease, hyponatremia, or severe cardiac conditions need clinician oversight before any oxytocin exposure.
- Hyponatremia or fluid-restricted conditions: oxytocin has antidiuretic activity that can cause water intoxication and seizures, especially with prolonged IV infusion.
- Hypersensitivity to oxytocin or chlorobutanol (the preservative in some IV formulations).
- Children and adolescents: studied in the SOARS-B autism trial, but ongoing dosing outside research settings is not supported by efficacy data.
- Anyone on lithium, prostaglandin analogues, or other agents with uterotonic or fluid-balance interactions should not combine those with oxytocin without clinician oversight.
Factors noted in the research literature; not patient-specific medical advice.
Regulatory Status
Regulatory status
RUO
Comparisons
Comparisons
| Compound | Mechanism | Route | Status |
|---|---|---|---|
| Oxytocinthis | A nonapeptide hormone acting on oxytocin receptors; studied for roles in uterine contraction, lactation, and central modulation of social and affiliative behavior. | subcutaneous | Investigational / RUO |
| Gonadorelin | A synthetic form of gonadotropin-releasing hormone (GnRH) acting on pituitary GnRH receptors to stimulate luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release, supporting the hypothalamic-pituitary-gonadal axis. | subcutaneous | Investigational / RUO |
| HCG | A glycoprotein hormone that binds LH receptors in the gonads, mimicking luteinizing hormone with a substantially longer half-life to stimulate gonadal steroidogenesis. | subcutaneous | Investigational / RUO |
| HMG | A purified gonadotropin preparation providing combined FSH and LH activity, acting on gonadal receptors to support gametogenesis and steroidogenesis. | subcutaneous | Investigational / RUO |
| PE-22-28 | A synthetic heptapeptide (GVSWGLR) derived from the sortilin propeptide that acts as a selective antagonist of TREK-1 potassium channels, a mechanism studied for mood regulation and neuroplasticity. | subcutaneous | Investigational / RUO |
| PEG MGF | A pegylated form of mechano growth factor designed for extended stability and systemic half-life; the C-terminal E-peptide is studied for satellite-cell activation and muscle repair. | subcutaneous | Investigational / RUO |
| Pinealon | A synthetic tripeptide bioregulator (Glu-Asp-Arg) studied for cell-penetrating, gene-regulatory activity in neural tissue, with proposed antioxidant and neuroprotective effects. | subcutaneous | Investigational / RUO |
Attributes shown for research comparison only; not a statement of efficacy or therapeutic equivalence.
FAQ
Frequently asked questions
Yes for one set of uses, no for others. IV and IM oxytocin injection USP is FDA-approved for labor induction, labor augmentation, postpartum hemorrhage control, and milk let-down support. Intranasal oxytocin, subcutaneous oxytocin, and sublingual oxytocin are not FDA-approved as of June 2026. They are investigational or research-use only.
Approximately 2 micrograms of pure peptide. That conversion is consistent across labels and PubChem chemistry data. So a 2 mg vial holds roughly 1,000 IU and a 5 mg vial holds roughly 2,500 IU.
Most human social-cognition trials use somewhere between 10 and 72 IU per session, with 24 IU being the most cited single-session dose since the Kosfeld 2005 Nature trust-game study. The SOARS-B autism trial used up to 48 IU per day split twice daily. These are research-arm doses, not personal recommendations.
Not for central nervous system effects. Subcutaneous oxytocin produces a quick rise in plasma levels but does not cross the blood-brain barrier in meaningful amounts. That is why research targeting brain oxytocin receptors (for example, social cognition) uses the intranasal route rather than subcutaneous.
Reconstituted research-use oxytocin in bacteriostatic water is typically considered usable for about 2-4 weeks when stored at 2-8 degrees Celsius (35.6 to 46.4 degrees Fahrenheit). Discard if it becomes cloudy or develops particulates. Approved injectable oxytocin solutions follow their own FDA-labeled storage instructions.
A common research-lab approach is to add 3.0 mL of bacteriostatic water, which gives about 1.67 mg/mL (roughly 833 IU/mL). On a U-100 insulin syringe, 10 units (0.10 mL) is then about 167 mcg or 83 IU. Use the reconstitution calculator to match BAC water volume to your target dose.
No. The SOARS-B trial (Sikich et al., NEJM 2021), with 290 children and adolescents over 24 weeks, found no significant difference between intranasal oxytocin and placebo on its primary or secondary social and cognitive endpoints. Smaller earlier studies had been more positive, but this larger trial is the strongest evidence to date.
There are small human studies suggesting oxytocin may reduce amygdala reactivity or change some anxiety-related measures, but it is not FDA-approved for any psychiatric condition and large trials have generally not supported clinical use. People considering this should talk to a licensed clinician rather than self-administer.
For IV obstetric use, the most important effects are uterine hyperstimulation, water intoxication with seizures, and maternal or fetal complications - which is why it is hospital-administered. For intranasal research-context use, observed effects are usually mild (nasal irritation, transient headache, occasional irritability). Subcutaneous research-context use can cause injection-site reactions.
No. This is an educational research summary, not personal medical advice. Approved oxytocin (Pitocin) is a hospital drug. Intranasal, subcutaneous, and sublingual oxytocin are investigational or research-use only. Anyone considering oxytocin in any form should talk with a licensed clinician.
Research-use notice
Research Use Only. This educational content and calculation support is intended for private research documentation. It does not provide medical advice, human-use directions, or claims of safety or effectiveness.